基于GABA受体的药物设计基于GABA受体的药物设计巨修练武汉工程大学GABA(-aminobutyricacid)OOHNH2ModelofGABAReceptorCl-ModelofCl-ChannelClClClClClClOOSOClClClClClClOOR4R3R6R5R2R7R1lindanea-endosulfanDTDPolychloratedCyclanesOOOHMeOOOOMeOOOOOOOHOOOHOOOpicrotoxininpicrodendrin-QtutiPicrodendrinHomologuesNNClClCF3NH2SOCF3CNSNOONNNOOfipronilLY219048U-93631PhenylpyrazolesOPOOSOOOOPOBrOTBPSEBOBdioxaphosphorinaneTrioxabicyclooctanesOPOR1OOOOR1OR2SSR1R2OR2R1OButylbenzoatesModificationofGABAAntagonistsOOOH3H3[3H]EBOBOOCOOHInhibitionof[3H]EBOBBindingLC50rat=1
41M,LC50fly=2
90MOPOOSOPOOSR4R3BicyclicGABAAntagonistsOPOOSNematocidalActivityLD50=24
7MOPOOSOPOOSLC50rat/LC50housefly=2360nM/45nM=52(invitro)Compound15LD50housefly=0
04mg/fly(invivo)OPOOSABCPresumptionofBindingSitesABCOOOPresumptionofBindingSitesEBOBR2OOR1ABCDPossibleInter